At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Contribution of De Novo Lipogenesis in Severity of Nonalcoholic Fatty Liver Disease
In Brief
An observational study for Nonalcoholic Fatty Liver Disease and 3 related conditions. Completed, enrolled 49 participants across 1 site.
Detailed Summary
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
CountriesUnited States
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartFeb 2019
Primary CompletionAug 2019
Study CompletionJul 2020
TodayJul 2026
First PostedSep 25, 2018
Enrollment StartFeb 1, 2019
Primary CompletionAug 21, 2019
Study CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.8 years ago